Next Article in Journal
Characterization of Anti-Ana o 3 Monoclonal Antibodies and Their Application in Comparing Brazilian Cashew Cultivars
Previous Article in Journal
Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
Previous Article in Special Issue
From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry
Article

Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies

1
Israel Institute for Biological Research, Ness-Ziona 7404800, Israel
2
The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel
*
Authors to whom correspondence should be addressed.
Academic Editors: Luis Martinez-Sobrido and James J. Kobie
Received: 16 September 2021 / Revised: 25 October 2021 / Accepted: 2 November 2021 / Published: 8 November 2021
The use of passively-administered neutralizing antibodies is a promising approach for the prevention and treatment of SARS-CoV-2 infection. Antibody-mediated protection may involve immune system recruitment through Fc-dependent activation of effector cells and the complement system. However, the role of Fc-mediated functions in the efficacious in-vivo neutralization of SARS-CoV-2 is not yet clear, and it is of high importance to delineate the role this process plays in antibody-mediated protection. Toward this aim, we have chosen two highly potent SARS-CoV-2 neutralizing human monoclonal antibodies, MD65 and BLN1 that target distinct domains of the spike (RBD and NTD, respectively). The Fc of these antibodies was engineered to include the triple mutation N297G/S298G/T299A that eliminates glycosylation and the binding to FcγR and to the complement system activator C1q. As expected, the virus neutralization activity (in-vitro) of the engineered antibodies was retained. To study the role of Fc-mediated functions, the protective activity of these antibodies was tested against lethal SARS-CoV-2 infection of K18-hACE2 transgenic mice, when treatment was initiated either before or two days post-exposure. Antibody treatment with both Fc-variants similarly rescued the mice from death reduced viral load and prevented signs of morbidity. Taken together, this work provides important insight regarding the contribution of Fc-effector functions in MD65 and BLN1 antibody-mediated protection, which should aid in the future design of effective antibody-based therapies. View Full-Text
Keywords: monoclonal antibodies (mAbs); SARS-CoV-2; fragment crystallizable (Fc); a-glycosylated; K18-hACE2 monoclonal antibodies (mAbs); SARS-CoV-2; fragment crystallizable (Fc); a-glycosylated; K18-hACE2
Show Figures

Figure 1

MDPI and ACS Style

Noy-Porat, T.; Edri, A.; Alcalay, R.; Makdasi, E.; Gur, D.; Aftalion, M.; Evgy, Y.; Beth-Din, A.; Levy, Y.; Epstein, E.; Radinsky, O.; Zauberman, A.; Lazar, S.; Yitzhaki, S.; Marcus, H.; Porgador, A.; Rosenfeld, R.; Mazor, O. Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies. Antibodies 2021, 10, 45. https://0-doi-org.brum.beds.ac.uk/10.3390/antib10040045

AMA Style

Noy-Porat T, Edri A, Alcalay R, Makdasi E, Gur D, Aftalion M, Evgy Y, Beth-Din A, Levy Y, Epstein E, Radinsky O, Zauberman A, Lazar S, Yitzhaki S, Marcus H, Porgador A, Rosenfeld R, Mazor O. Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies. Antibodies. 2021; 10(4):45. https://0-doi-org.brum.beds.ac.uk/10.3390/antib10040045

Chicago/Turabian Style

Noy-Porat, Tal, Avishay Edri, Ron Alcalay, Efi Makdasi, David Gur, Moshe Aftalion, Yentl Evgy, Adi Beth-Din, Yinon Levy, Eyal Epstein, Olga Radinsky, Ayelet Zauberman, Shirley Lazar, Shmuel Yitzhaki, Hadar Marcus, Angel Porgador, Ronit Rosenfeld, and Ohad Mazor. 2021. "Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies" Antibodies 10, no. 4: 45. https://0-doi-org.brum.beds.ac.uk/10.3390/antib10040045

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop